Business
CSL and research partners give up on plans to develop COVID treatment – Sydney Morning Herald
Australia’s local vaccine producer and its partners have been forced to shelve research on a possible COVID treatment after its phase 3 trial failed to convince…
While the results of this particular clinical trial are disappointing, we are proud that as an industry we proactively and collaboratively pursued this work, and that the program may contribute to a growing understanding of this challenging virus and strategies for patient care, said Bill Mezzanotte, executive vice president and head of research and development and chief medical officer at CSL Behring.
Since we embarked on this development program, and throughout the pandemic, we have learned much…
Continue Reading
